Addictions are chronic brain diseases that can be treated medically
Opiant is a pharmaceutical company with a mission to create best-in-class medicines for the treatment of addictions and drug overdose.
We are headquartered in Santa Monica, with additional offices in London, UK.
Statistics
Patient Population with Addictions and Drug Overdose
Over 20 million people are affected by addictions and drug overdose in the United States.
with emergency room visits with Acute Cannabinoid Overdose
with Alcohol Use Disorder
with Opioid Use Disorder and 48k opioid-related overdose deaths annually
SCIENCE & TECHNOLOGY
Effective Medicines with Optimized Delivery Solutions
Opiant takes several approaches to treating addictions and drug overdose, with the goal of using the optimal pathway for drug delivery. Although we’ve demonstrated our core competency in intranasal delivery with NARCAN® Nasal Spray and have expanded that usage to our clinical pipeline in overdose and addiction, we are exploiting more effective delivery options for our preclinical programs and their respective indications.
- Nasal Sprays – single-use for overdose and ‘as-needed/on-demand’ for Alcohol Use Disorder
- Injection – a vaccine for heroin and single-use for Acute Cannabinoid Overdose
- Implant – lasting up to 6 months for Opioid Use Disorder
PIPELINE
Our Pipeline
In response to a growing public health need, Opiant is developing products to treat addictions and drug overdose.
Spotlight
The Latest from Opiant
Combating America’s Opioid Crisis – Fox & Friends
April 11, 2019 – Opiant CEO Dr. Roger Crystal discusses treating opioid addiction with marijuana.
Fighting the Opioid Crisis – Fox Business Network’s “Mornings with Maria”
August 3, 2018 – Opiant CEO Dr. Roger Crystal discusses NARCAN® following singer Demi Lovato’s hospitalization.
Meeting of the President’s Commission on Combating Drug Addiction and Opioid Crisis
September 27, 2017 – Opiant CEO Dr. Roger Crystal testifies before the President’s Commission on Combating Drug Addiction and the Opioid Crisis.
Opiant Pharmaceuticals Strengthens Management Team with Appointments of Chief Commercial Officer and General Counsel
SANTA MONICA, Calif. , Sept. 17, 2019 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and…
Opiant Pharmaceuticals Announces Presentations at Two Upcoming Investor Conferences
SANTA MONICA, Calif. , Aug. 27, 2019 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and…
Opiant Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update
SANTA MONICA, Calif. , Aug. 08, 2019 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and…
September 9, 2019 3:50 PM EDT : Opiant Pharmaceuticals at H.C. Wainwright 21st Annual Global Healthcare Conference
September 5, 2019 10:20 AM EDT : Opiant Pharmaceuticals at 2019 Wells Fargo Securities Healthcare Conference
May 9, 2019 4:30 PM EDT : Opiant Pharmaceuticals First Quarter 2019 Financial Results Conference Call
Fighting fire with fire: development of intranasal nalmefene to treat synthetic opioid overdose
Published in April 2019 by ASPET Journals.
Intranasal naloxone rapidly occupies brain mu-opiod receptors in human subjects
Published in March 2019 by American College of Neuropsychopharmacology.
Enhanced Intranasal Absorption of Naltrexone by Dodecyl Maltopyranoside: Implications for the Treatment of Opioid Overdose
Published in 2019 by the Journal of Clinical Pharmacology.